Table 2 Comparison of patient’s characteristics
From: Renal AA-amyloidosis in intravenous drug users – a role for HIV-infection?
AA-Amyloidosis | Other renal | p-value | |
|---|---|---|---|
(n=12) | disease (n=12) | ||
Age (years) | 39.5 (32 – 44) | 43.5 (33 – 48) | 0.563 |
Male – n (%) | 9 (75.0%) | 6 (50%) | 0.400 |
Self-reported time after initiation of IVDU (years) | 22 (17 – 31) | 19.5 (11 – 29) | 0.418 |
Self-reported duration of IVDU (years) | 20.5 (14 – 27) | 12.5 (7 – 19) | 0.056 |
History of opioid maintenance therapy | 5 (41.7%) | 7 (58.3%) | 0.684 |
Chronic hepatitis B | 1 (4.2%) | 0 (0%) | 1.0 |
Chronic hepatitis C | 10 (83.3%) | 11 (91.7%) | 1.0 |
HIV | 8 (66.7%) | 2 (16.7%) | 0.036 |
Medical history of | |||
Chronic or repeated skin infections | 11 (91.7%) | 6 (50.0%) | 0.069 |
Bacterial endocarditis | 2 (16.7%) | 1 (8.3%) | 1.000 |
Repeated pneumonia | 8 (66.7%) | 3 (25.0%) | 0.100 |
Serum creatinine (mg/dl) | 2.5 (1.9 – 4.0) | 2.4 (1.7 – 3.2) | 0.902 |
Proteinuria (g/24 h) | 8.9 (7.5 – 19.1) | 4.1 (1.5 – 9.8) | 0.021 |
Serum albumin | 2.2 (1.5 – 2.8) | 3.0 (2.0 – 3.9) | 0.124 |
Total serum protein | 6.2 (5.3 – 7.2) | 6.1 (4.9- 7.4) | 0.853 |
Peripheral edema | 3 (25.0%) | 4 (33.3%) | 1.0 |
Hypertension | 1 (8.3%) | 5 (60.0%) | 0.1 |